Fig. 1: The ability of STING agonists to activate STING and enhance the humoral immune response in mice. | Cell Research

Fig. 1: The ability of STING agonists to activate STING and enhance the humoral immune response in mice.

From: A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs

Fig. 1

a The structures of the STING agonists. b THP-1 cells were treated with the indicated STING agonists (10 µM) for 3 h. Cells were lysed, and immunoblotting assay was used to determine the protein expression levels. c Activation of IFN-β, IL-6, CXCL-10, TNF-α, ISG15 and CCL-5 following 5-h incubation with the STING agonists. Data shown are means ± SEM. d THP-1 cells were treated with DMSO or 10 µM CF501 for 5 h. Total RNA was extracted for RNA-seq analysis. Heatmap shows the differentially expressed genes with Log2 fold change > 2 or <–2 and an adjusted P value < 0.05. e SARS-CoV-2 RBD-specific binding IgG, IgG1, and IgG2a endpoint titers are shown at day 21 and day 35. Data shown are geometric means ± SD from six samples. Statistical analyses were performed using one-way ANOVA. *P < 0.05, **P < 0.001, ***P < 0.0001.

Back to article page